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Abbrevations: AID: activation-induced cytidine deaminase; Bcl-6: B cell lymphoma 6 
protein; Breg: regulatory B cell; B10: IL-10 producing B cell; B10PRO: B10 progenitor 
cells; CD: Cluster of Differentiation; CCR7: C-C chemokine receptor type 7; CXCL10: 
C-X-C chemokine ligand 10; C-X-C chemokine receptor 5: CXCR5; DCs: dendritic 
cells; DN: double-negative; EGMs: extraglandular manifestations; FITC: fluorescein 
isothiocyanate; GC: germinal centre; ICOS: inducible T cell co-stimulator; IL: 
interleukin; LSG: labial salivary gland; PD-1: programmed cell death protein 1; PE: R-
phycoerythrin; PE-Cy5: R-phycoerythrin-Cyanine dye 5; PerCP-Cy5.5: Peridinin-
chlorophyll protein-Cyanine dye 5.5; pSS: primary Sjögren´s syndrome; RF: 
rheumatoid factor; Tr1: type 1 regulatory T cell; SLE: systemic lupus erythematosus; 
TFH: T follicular helper 
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Summary 
 
Follicular T helper (TFH) cells have a crucial role in regulating immune responses within 
secondary lymphoid follicles by directing B cell differentiation toward memory B cells 
and plasma cells. Since abnormal humoral responses are key features in both primary 
Sjögren’s syndrome (pSS) and systemic lupus erythematosus (SLE), the aim of this 
study was to profile the pathological connection between peripheral TFH cells and B 
cells in the two diseases. Twenty-five pSS patients, 25 SLE patients and 21 healthy 
controls were enrolled in the study. We determined the ratio of circulating TFH-like 
cells, their IL-21 production, and different B cell subsets by flow cytometry. We 
observed higher percentages of naive B cells in both diseases, while non-switched and 
switched memory B cells showed decreased frequencies. The proportions of double-
negative B cells and plasmablasts were elevated in SLE and decreased in pSS. The 
percentages of transitional B cells and mature-naive B cells were higher in SLE. 
Patients with more severe disease course had elevated ratio of TFH-like cells and 
increased IL-21 production. Moreover, expansion of TFH-like cells correlated positively 
with parameters related to antibody secretion, including serum IgG, ICs and 
autoantibodies. Correlation analysis between TFH-like cells and certain B cell subsets 
revealed possible defects during B cell selection. In conclusion, our observations on the 
profound expansion of circulating TFH-like cells and their IL-21 production along with 
the characteristic aberrant peripheral B cell distribution in both pSS and SLE indicate 
the prominent role of TFH cell in the regulation of B cell selection. 
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Introduction 
 
Autoimmune diseases are characterized by the breakdown of immune tolerance leading 
to autoreactive immune mechanisms and consequential tissue and organ damages. In the 
pathogenesis of autoimmune diseases, various cellular and humoral immune processes 
have been described, including disproportional T and B cell responses, altered cytokine 
milieu and disturbed apoptotic processes, which result in exaggerated immune 
responses. In the last decades, a large amount of studies confirmed that B cell activation 
plays a crucial role in the inflammatory processes through antigen presentation, 
autoantibody production and secretion of numerous pro-inflammatory factors. However, 
besides the established disease-promoting role of B cells, certain B cell subsets, so-
called regulatory B (Breg) cells have a negative regulatory effect by producing 
regulatory cytokines such as IL-10, and directly interacting with activated T cells via 
cell-to-cell contact 1. 
The proliferation and differentiation of B cells highly depend on their collaboration with 
a special subset of CD4+ T cells in the germinal centres (GCs) of secondary lymphoid 
organs. These recently described T cells, so-called follicular helper T (TFH) cells, are 
generated from peripheral naive CD4+ T cells in the T cell zone of lymphoid organs. 
The proper interplay of activated B cells and TFH cells is essential for the development 
of extrafollicular short-lived, low-affinity plasma cells and also for GC responses. 
Within GCs, TFH cells facilitate the generation of high-affinity memory B cells and 
long-lived plasma cells. IL-21 is the hallmark cytokine of TFH cells and has been shown 
to function as a potent inducer of plasma cell formation; moreover, it is involved in GC 
B cell selection, as well 2.  
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Considering the critical role of TFH cells and their IL-21 cytokine secretion in B cell 
activation and antibody production, their failure to maintain self-tolerance and potential 
contribution to autoimmunity drew an intensive attention. Recent investigations shed 
light on altered TFH profiles in various autoimmune conditions. In systemic lupus 
erythematosus (SLE), which is a prototypic systemic autoimmune disease characterised 
by immune complex-mediated systemic tissue damage, it is well established that the 
imbalance of different subsets of B cells is crucial for the initiation and perpetuation of 
the disease. Recently, elevated percentages of peripheral CD4+ICOShigh and 
CD4+CXCR5+ICOShigh TFH cells were reported in SLE patients. Notably, these cell 
proportions showed associations with autoantibody titres and the presence of 
glomerulonephritis, as well 3. Moreover, corticosteroid pulse therapy down-regulated 
the number of circulating TFH cells, indicating that TFH cells may be good therapeutic 
targets in the disease 4. 
In primary Sjögren’s syndrome (pSS), which is a common systemic autoimmune 
disease characterized by chronic inflammation and consequential destruction of 
exocrine glands, humoral autoimmune responses, B cell activation and autoantibody 
production are key immune abnormalities, as well. Immunohistological analysis of 
biopsies from minor salivary glands commonly demonstrates the presence of ectopic 
GCs in pSS. The number of GCs in salivary glands correlates with the severity of 
inflammation, and anti-SSA/Ro and anti-SSB/La autoantibody-production. Moreover, 
the formation of ectopic GCs carries a higher risk of developing B cell lymphoma 5. 
Recently, we demonstrated elevated circulating CD4+CXCR5+ICOS+PD-1+ TFH cell 
percentages in pSS. Based on our data, we found a strong association between the TFH 
cell proportions and the presence of systemic extraglandular manifestations (EGMs) and 
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anti-SSA/SSB autoantibody positivity. Patients with higher TFH cell proportions also 
had elevated serum levels of IL-12 and IL-21 6. Maehara et al. described that the 
expression of Th2 and certain TFH-related molecules was associated with robust 
lymphocytic accumulation and ectopic GC formation 7. We also investigated the 
localization of TFH cells in the lymphocyte infiltration in labial salivary gland 
(LSG) biopsies gained from pSS patients at the time of disease onset, and found that 
TFH cell markers (CD84, PD-1, and Bcl-6) occurred predominantly in more organized 
lymphoid structures with higher focus scores 8, which indicates that TFH cells may be 
good therapeutic targets in pSS, as well. 
However, the complex interplay between TFH cells and the special subsets of B cells is 
not yet fully elucidated. Since identification of the pathogenic pathways and the 
corresponding biomarkers linking abnormal cellular activity to disease activity and 
outcome is essential for defining proper therapeutic targets, the aim of the present study 
was to profile the pathological connection between the peripheral TFH cells and B cell 
subsets and the clinical features of pSS and SLE. 
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Materials and methods 
 
Patients and healthy individuals 
Total of 25 patients with pSS (24 female and 1 male; mean age: 57.88 ± 9.19 years) and 
25 patients with SLE (24 female and 1 male; mean age: 41.17 ± 13.20 years) were 
enrolled in the study. All patients were recruited from the Outpatient Clinic for systemic 
autoimmune diseases at the Division of Clinical Immunology, University of Debrecen, 
where they received regular follow-up treatment. The average disease duration in case 
of pSS was 13.40 ± 7.94 years, while 11.44 ± 9.14 years in SLE. The diagnosis of pSS 
was based on the European-American consensus criteria 9. Among pSS patients, 15 
suffered from extraglandular manifestations (EGMs), while 10 had only glandular 
symptoms. The distribution of EGMs of pSS patients were as follows: polyarthralgia 
n=11, Raynaud’s phenomenon n=7, polyarthritis n=6, vasculitis n=2. The exclusion 
criteria included therapy with immunosuppressive/immunomodulant agents. Vasculitis 
or other EGMs needing immunosuppressive treatment were newly recognised. All 
patients with SLE fulfilled the corresponding diagnostic criteria for lupus 10, 11; and their 
disease activity was assessed by the SLE Disease Activity Index (SLEDAI). SLE 
patients were classified according to having inactive or active disease status: 
SLEDAI<6 group comprised subjects with inactive disease (n=17), while SLEDAI≥6 
group consisted of subjects with active disease (n=8). All of the SLE patients received 
per os methylprednisolone therapy with an average dose of 4 mg daily; the dose of the 
treatment did not exceed 8 mg methylprednisolone per day in any case of SLE patients. 
The blood samples were collected from SLE patients 24 hours after taking the regular 
methylprednisolone medication. The active disease status in the corresponding SLE 
patients was newly recognised, and these patients undergone the blood sampling before 
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any changes in their therapy. In addition, patients were also categorized according to 
their serological markers with a special emphasis on the presence of autoantibodies. 
Among pSS patients, we found 9 anti-Ro/SSA positive (SSA>10 U/ml) individuals, 4 of 
them were anti-Ro/SSA – anti-La/SSB double positive. Regarding SLE patients, 15 of 
them were anti-dsDNA positive (dsDNA>20 IU/ml). The control group consisted of 21 
age- and sex-matched (20 female and 1 male; mean age: 39.10 ± 12.43years) healthy 
volunteers. No patients or controls enrolled in this study had ongoing infections, either 
viral or bacterial. Informed written consent was obtained from all subjects, and the 
study was approved by the Ethics Committee of the University of Debrecen. All 
experiments carried out were in compliance with the Declaration of Helsinki. 
 
Cell surface staining and flow cytometric analysis 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinised venous 
blood sample by Ficoll-Histopaque (Sigma-Aldrich, St Louis, MO, USA) density-
gradient centrifugation. Cells were then harvested and washed twice and stained for 20 
min at 4°C using specific antibodies. For identification of naive and memory B cell 
subsets, we used IgD-fluorescein isothiocyanate (FITC) (clone: IADB6)/CD27-
phycoerythrin (PE) (clone: 1A4CD27)/CD19-phycoerythrin-Cyanine dye 5 (PE-Cy5) 
(clone: J3-119) (all from Beckman Coulter Inc, Fullerton, CA, USA and Immunotech, 
Marseille, France). To identify naive, mature-naive, primarily memory and transitional 
B cell subpopulations, cells were stained with the following combination of monoclonal 
antibodies: CD38-FITC (clone: HIT2)/CD27-PE/CD19-PE-Cy5/CD24-allophycocyanin 
(APC) (ML5) (BD Biosciences, San Diego, CA, USA and Beckmann Coulter and 
BioLegend, San Diego, CA, USA). At least 20.000 CD19+ events of each sample were 
analysed within the whole lymphocyte population. For the assessment of circulating TFH 
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cells we used CXCR5-Alexa Fluor 488 (clone: RF8B2)/ICOS-PE (clone: DX29)/PD-1-
Peridinin-chlorophyll protein-Cyanine dye 5.5 (PerCP-Cy5.5) (clone: EH12.1)/CD4-
APC (clone: RPA-T4) (all from BD Biosciences) monoclonal antibodies. For the 
determination of naive and activated or memory CD4+ T cell subsets we used CD45RA-
PE (clone: HI100) and CD45RA-PerCP-Cy5.5 (clone: HI100) monoclonal antibodies 
(both from BioLegend). Fluorescence Minus One controls were used in all procedures. 
The stained cells were measured by FACS Calibur flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ, USA) and data were analysed using FlowJo Software (Treestar, 
Ashland, OR, USA). In case of TFH cells at least 75.000 CD4+ events per sample were 
analysed within the whole lymphocyte population. 
 
Intracellular cytokine analysis by flow cytometry 
The cytoplasmic IL-21 content of circulating TFH cells was also determined by flow 
cytometry. Briefly, isolated PBMCs were cultured in modified RPMI 1640 medium 
with GLUTAMAXTM-I (Life Technologies Corporation, Carlsbad, CA, USA) 
supplemented with 100 U/ml penicillin, 100 ng/ml streptomycin and 10% heat-
inactivated fetal calf serum (Life Technologies) at a concentration of 2x106/ml in 24-
well tissue culture plates for analysing single-cell cytokine production. Total PBMCs 
were incubated with phorbol-12-myristate 13-acetate (PMA) (25 ng/ml), ionomycin (1 
µg/ml), and Golgi Stop brefeldin-A (10 µg/ml) (all from Sigma Aldrich) for 5 h at 37°C 
in 5% CO2 milieu. Cell surface staining was performed with a cocktail of CXCR5-
AF488, PD-1-PerCP-Cy5.5 and CD4-APC monoclonal antibodies for 20 min at 4°C. 
The cells then fixed and permeabilized with IntraprepTM permeabilization reagent 
(Beckman Coulter Inc, Miami, FL, USA) according to the manufacturer's instructions, 
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and intracellular cytokines were stained with anti-IL-21-PE (clone: 3A3-N2.1) (BD 
Biosciences).  
For intracellular IL-10 induction of B cells, PBMCs were stimulated with CpG (Toll-
like receptor 9 ligand, ODN 2006 type B; 0.5 µM/ml; Hycult Biotech Inc., Uden 
The Netherlands) for 48 h at 37°C in 5% CO2 milieu. For the last 5 h, PMA (25 ng/ml), 
ionomycin (1 µg/ml), and Golgi Stop brefeldin-A (10 µg/ml) were added to the culture. 
Cells were then harvested, washed in staining buffer, and incubated for 20 min at 4°C 
with CD19-PE-Cy5. Intracellular staining method was performed with IL-10-PE (clone: 
JES3-9D7) as described above. Measurements were performed and data were collected 
by FACS Calibur flow cytometer and data were analysed using FlowJo Software. At 
least 75.000 CD4+ events or 15.000 CD19+ events of each sample were analysed within 
the entire lymphocyte population. The viability of the CpG exposed cells were 
determined by 7-aminoactinomycin-D (7-AAD; BioLegend) staining with flow 
cytometric analysis. The identification of B cells was performed with CD19-FITC 
(clone J3-119) monoclonal antibody. The percentages of dead cells among the CD19+ B 
cells were increased in the PIB and CpG+PIB group, however the average percentages 
of dead cells remained <2.5 %. Regarding the whole lymphocyte group, the proportions 
of dead cells did not exceed 5% on average (Fig S1). 
 
Assessment of anti-dsDNA, anti-Ro/SSA and anti-La/SSB autoantibodies 
As part of the routine diagnostic evaluation, autoantibodies were determined by ELISA 
technique with AUTOSTAT II kits (Hycor Biomedical, Indianapolis, IN, USA) 
according to the manufacturer’s instructions. 
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Statistical analysis 
Data were represented and statistical analysed with GraphPad Prism 5 software 
(Graphpad Software, San Diego, USA). Data are presented as mean ± SD. To assess the 
distribution of the data Shapiro-Wilk normality test were used. In cases of normal 
distribution, if the F probe was granted we used unpaired t test, otherwise it was not 
granted we used unpaired t test with Welch’s correction for statistical comparison of the 
experimental data. In cases if distributions the data set was different from normal, the 
Mann–Whitney U test was used. The correlations between two variables were evaluated 
with Pearson's correlation coefficient, while in cases of non-normal distribution, 
Spearman's test was used. Differences were considered statistically significant at p < 
0.05. 
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Results 
 
The distribution of peripheral B cell subpopulations 
According to the expression of IgD, CD27, CD38 and CD24 cell surface markers, the 
following B cell subsets were identified: CD19+IgD+CD27- naive B cells, 
CD19+IgD+CD27+ non-switched memory B cells, CD19+IgD-CD27+ switched memory 
B cells, CD19+IgD-CD27- double negative (DN) B cells, CD19+CD38-CD24hiCD27+ 
primarily memory B cells, CD19+CD38hiCD24hiCD27- transitional B cells, 
CD19+CD38+CD24+ mature-naive B cells and CD19+CD38hiCD27hi plasmablasts. Cells 
were quantified as their percentage in the CD19+ lymphocyte population.  
Regarding CD19+IgD-CD27+ B cells, percentages were decreased in the overall pSS 
patient population compared to values in healthy individuals (15.07 ± 7.65% vs. 23.23 ± 
6.78%, respectively, p=0.0005) (Fig. 1a). Correspondingly, both subgroups of pSS 
patients had significantly lower percentages compared to controls (pSS without EGMs 
vs. control: 17.30 ± 5.06% vs. 23.23 ± 6.78%, respectively, p=0.0207; pSS with EGMs 
vs. control: 13.58 ± 8.83% vs. 23.23 ± 6.78%, respectively, p=0.0007) (Fig. 1a). On the 
contrary, CD19+IgD-CD27+ B cell percentages in the total SLE patient population and 
controls were similar. However, SLE patients with SLEDAI<6, unlike patients with 
SLEDAI>6, had significantly decreased CD19+IgD-CD27+ B cell percentages compared 
to controls (17.53 ± 13.89% vs. 23.23 ± 6.78%, respectively, p=0.0321).  
The ratio of CD19+IgD+CD27+ B cells was significantly lower in the whole SLE group 
than in healthy individuals (10.98 ± 10.60% vs. 21.64 ± 11.52%, respectively, 
p=0.0019) (Fig. 1b). This observation was also valid for SLEDAI<6 and SLEDAI>6 
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patient subgroups separately, as well (13.21 ± 11.88% vs. 21.64 ± 11.52%, respectively, 
p=0.0333 and 6.25 ± 5.03% vs. 21.64 ± 11.52%, respectively, p<0.0001) (Fig. 1b).  
Peripheral CD19+IgD-CD27- DN B cell proportions were significantly reduced in the 
overall pSS patients group set against to control values (3.214 ± 2.463% vs. 3.796 ± 
1.681%, respectively, p=0.0290). However, intragroup differences could be found only 
in pSS patients with EGMs when compared to controls (3.306 ± 3.030% vs. 3.796 ± 
1.681%, respectively, p=0.0291) (Fig. 1c). Interestingly, in contrast to measurements in 
pSS, the percentages of CD19+IgD-CD27- DN B cells were significantly heightened in 
whole SLE group than in healthy individuals (6.906 ± 4.525% vs. 3.796 ± 1.681%, 
respectively, p=0.0119). Nevertheless, this significant change could be detected only in 
SLEDAI<6 patient subgroup compared to controls (7.017 ± 4.998% vs. 3.796 ± 
1.681%, respectively, p=0.0204) (Fig. 1c). 
The percentages of CD19+IgD+CD27- B cells were significantly increased in the whole 
pSS patient group compared to controls (63.87 ± 20.76% vs. 51.32 ± 15.14%, 
respectively, p=0.0261); however, this significant elevation could be observed only in 
pSS patients without EGMs (63.70 ± 14.14% vs. 51.32 ± 15.14%, respectively, 
p=0.0382) (Fig. 1d). Frequency of CD19+IgD+CD27- B cells was also significantly 
elevated in the total SLE patient group (62.88 ± 21.87% vs. 51.32 ± 15.14%, 
respectively, p=0.0471) (Fig. 1d). Certainly, this tendency was also found in the 
remaining patient subgroups, however the differences were not significant. 
The percentages of CD19+CD38-CD24hiCD27+ B cell ratio was significantly decreased 
in pSS patients without EGMs when compared to healthy subjects (23.29 ± 9.827% vs. 
34.58 ± 13.91%, respectively, p=0.0289) (Fig. 1e), of note, this difference was observed 
between pSS with EGMs and healthy subjects.  The frequency of CD19+CD38-
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CD24hiCD27+ B cells were significantly reduced in the whole SLE patient group and 
SLEDAI>6 group, compared to control values (22.77 ± 14.45% vs. 34.58 ± 13.91%, 
respectively, p=0.0074 and 17.10 ± 12.11% vs. 34.58 ± 13.91%, respectively, 
p=0.0042) (Fig. 1e).  
There was no difference in the pSS groups regarding the distribution of both 
CD19+CD38hiCD24hiCD27- and CD19+CD38+CD24+ B cell subsets. However, this 
could be due to the low number of patients in the sub-divided groups. On the other 
hand, we found that the ratio of CD19+CD38hiCD24hiCD27- B cells was significantly 
elevated in pSS patients with the presence of anti-Ro/SSA antibody compared to subject 
whom autoantibody levels were under the threshold value (9.842 ± 7.766% vs. 3.722 ± 
2.320%, respectively, p=0.0499) (data not shown). In the overall SLE group and in 
patients with SLEDAI>6, the frequency of CD19+CD38hiCD24hiCD27- B cells was 
significantly higher than control values (10.35 ± 7.78% vs. 5.30 ± 2.42%, respectively, 
p=0.0045 and 12.71 ± 7.73% vs. 5.30 ± 2.42%, respectively, p=0.0323) (Fig. 1f). 
Furthermore, the ratio of CD19+CD38+CD24+ B cells was also significantly elevated not 
only in the total SLE group, but in the SLEDAI>6 group compared to those measured in 
healthy subjects (35.86 ± 14.86% vs. 27.74 ± 9.33%, respectively, p=0.0297 and 39.32 
± 11.61% vs. 27.74 ± 9.33%, respectively, p=0.0094) (Fig. 1f).  
The ratio of peripheral CD19+CD38hiCD27hi plasmablasts showed a different tendency 
in the two disease. The percentages of these cells were significantly lower in the overall 
group of pSS patient, as well as in the patients with EGMs groups than control values 
(0.134 ± 0.154% vs. 0.267 ± 0.293%, respectively, p=0.0050 and 0.127 ± 0.183% vs. 
0.267 ± 0.293%, respectively, p=0.0014) (Fig. 1h). However, in patients with SLE, we 
found significantly higher frequency of CD19+CD38hiCD27hi plasmablasts only in 
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SLEDAI>6 group compared to healthy subjects (1.150 ± 1.181% vs. 0.2671 ± 0.2932%, 
respectively, p=0.0403) (Fig. 1h). 
 
Quantification of circulating TFH-like cells 
Circulating TFH-like cells were quantified as their percentages within the CD4+ 
lymphocytes of peripheral blood. Within CD4+CXCR5+ lymphocytes, we also 
determined the fraction of ICOS+PD-1+ T cells. According to our results, the 
percentages of CD4+CXCR5+ICOS+PD-1+ TFH-like cells were significantly increased in 
pSS patients with EGMs when compared to pSS patients with glandular symptoms and 
healthy controls (0.4121 ± 0.2753% vs. 0.2253 ± 0.1238%, respectively, p=0.0322 and 
0.4121 ± 0.2753% vs. 0.2235 ± 0.0979%, respectively, p=0.0218) (Fig. 2a). The 
frequency of TFH-like cells was also elevated in SLE, however this difference was 
significant only when the overall SLE patients were compared with the controls (0.3369 
± 0.2029% vs, 0.2235 ± 0.0979%, respectively, p=0.0184) (Fig. 2a). Additionally, we 
analysed the distribution of TFH cells percentages in the patient groups according to the 
absence or presence of specific autoantibodies. The ratio of TFH cells showed a 
significant 2-fold increase in anti-Ro/SSA antibody-positive group compared to healthy 
controls and anti-Ro/SSA antibody-negative group as well (0.4806 ± 0.2699% vs. 
0.2235 ± 0.0979%, respectively, p=0.0050 and 0.4806 ± 0.2699% vs. 0.2568 ± 
0.1893%, respectively, p=0.0138) (Fig. 2b). Regarding anti-dsDNA antibody-positive 
group, we found a significant 1.6-fold increase compared to control values (0.3717 ± 
0.2153% vs. 0.2235 ± 0.0979%, respectively, p=0.0192) (Fig. 2b).  
We also determined CD45RA+ naive CD4+ T cells and CD45RA- activated or memory 
CD4+ T cells in a smaller groups of patients and controls (pSS n=9, SLE n=8 and 
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control n=6). Then we measured the ratio of CXCR5+ICOS+ or CXCR5+PD-1+ cells in 
both CD4+CD45RA- and CD4+CD45RA+ subsets. Naive CD45RA+ T cells mostly 
showed reduced ICOS and PD-1 expression compared to activated or memory 
CD45RA- T cells. The ratio of CXCR5+ICOS+ cells were increased in patients with pSS 
and SLE in the CD4+CD45RA+ subset, although the values were generally under 
0.25%. The percentages of CXCR5+ICOS+ cells were elevated especially in SLE and 
the values varied between 0.120-1.310%. The ratios of CXCR5+PD-1+ cells were also 
increased in both disease and showed similar tendency: the values were generally under 
0.68% in the CD4+CD45RA+ subset, while those were between 1.280-12.10% in the 
CD4+CD45RA- T cells. Moreover, we investigated the association between the ratios of 
CXCR5+ICOS+ cells and CXCR5+PD-1+ cells in the CD4+CD45RA- subsets, as well, 
and we found a significant positive correlation in the whole measured group (R=0.6393, 
respectively, p=0.0010) (Fig. S2). 
 
Measurement of individual cytokine production of circulating TFH cells 
To establish the cytokine profile of circulating TFH-like cells, we determined 
intracellular IL-21 cytokine production. The frequency of IL-21 producing 
CD4+CXCR5+PD-1+ cells did not differ significantly between the whole group of pSS 
patients and healthy controls. However, we found that the percentages of 
CD4+CXCR5+PD-1+IL-21+ T cells were significantly higher in pSS patients with EGMs 
than control values (0.2449 ± 0.1657% vs. 0.1469 ± 0.0649%, respectively, p=0.0442) 
(Fig. 2c). The ratio of IL-21 producing TFH-like cells was significantly elevated in the 
overall SLE group, and in both SLE subgroups (SLEDAI<6 and SLEDAI>6 groups) 
compared to those measured in controls (0.3125 ± 0.1886% vs. 0.1469 ± 0.0649%, 
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respectively, p=0.0003, 0.2786 ± 0.1805% vs. 0.1469 ± 0.0649%, respectively, 
p=0.0100 and 0.3846 ± 0.1968% vs. 0.1469 ± 0.0649%, respectively, p=0.0123) (Fig. 
2c). When we measured the percentages of TFH cells in patients with pSS with an 
emphasis on the presence of autoantibodies, the percentages of TFH cells showed a 
significant 1.8-fold increase in anti-Ro/SSA antibody-positive pSS group compared to 
controls (0.2742 ± 0.1418% vs. 0.1469 ± 0.0649%, respectively, p=0.0297) (Fig. 2d). In 
SLE patients, we found significant 2.5-fold higher percentages of TFH cells in anti-
dsDNA antibody-positive SLE group compared to healthy controls (0.3638 ± 0.1982% 
vs. 0.1469 ± 0.0649%, respectively, p=0.0009); additionally, 1.5-fold higher ratios of 
TFH cells compared to anti-dsDNA antibody-negative SLE group (0.3638 ± 0.1982% vs. 
0.2356 ± 0.1509%, respectively, p=0.0489) (Fig. 2d). Additionally, we investigated the 
possible associations between the ratio of CD4+CXCR5+ICOS+PD-1+ TFH-like cells and 
IL-21 producing CD4+CXCR5+PD-1+ T cells. A significant positive correlation was 
found in pSS patient group (R=0.5915, respectively, p=0.0018) and a positive, but not 
significant association observed in SLE patient group (R=0.3862, respectively, 
p=0.0566) (Fig. 3). 
 
Assessment of IL-10 producing B cells 
As a next step, we cultured PBMCs for 5 h or 48 h, stimulated them with PIB alone or 
in combination with CpG, and then determined the ratios of IL-10 producing CD19+ B 
cells. After 5-hour incubation with PIB + CpG, we found no significant differences in 
the ratio of IL-10+CD19+ B cells between patient groups and healthy controls (Fig. 4a). 
However, after 48 h incubation period and stimulation with PIB alone for the last 5 h, 
we found that the percentages of IL-10+CD19+ B cells in the pSS patient group were 
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significantly decreased than those measured in controls and SLE patient group (0.9688 
± 0.4284% vs. 1.592 ± 0.8799%, respectively, p=0.0076 and 0.9688 ± 0.4284% vs. 
1.645 ± 1.198%, respectively, p=0.0127) (Fig. 4b). Furthermore, IL-10+CD19+ B cell 
percentages were determined after in vitro B10PRO cell maturation by stimulation with 
CpG for 48 h with PIB added for the final 5 h to the culture. The total frequency of IL-
10 producing CD19+ B cells including B10 and matured B10PRO cells, was significantly 
elevated compared with PIB alone treated cells in case of each equivalent groups 
(control: 5.543 ± 2.372% vs. 1.592 ± 0.8799%, respectively, p<0.0001; pSS: 5.712 ± 
0.3.310% vs. 0.9688 ± 0.4284%, respectively, p<0.0001 and SLE: 6.342 ± 4.023% vs. 
1.645 ± 1.198%, respectively, p<0.0001) (Fig. 4b). However, there were no significant 
differences between the patients groups and healthy controls regarding the distribution 
of IL-10+CD19+ B cells after 48 h of CpG stimulation. 
 
Correlation analysis between peripheral TFH-like cells and certain B cell 
subpopulations in pSS  
We measured the relationship between the percentages of CD19+CD38hiCD24hiCD27- 
transitional B cells and the proportions of both CD4+CXCR5+ICOS+PD-1+ TFH-like 
cells and CD4+CXCR5+PD-1+IL-21+ TFH cells in pSS. We revealed a positive but not 
significant correlation between the ratio of transitional and TFH-like cells (R=0.3389, 
respectively, p=0.0975), moreover a significant positive correlation between transitional 
B cells and IL-21 producing TFH cells in the overall pSS group (R=0.4455, respectively, 
p=0.0256) (data not shown). When we focused only on pSS patients with EGMs, we 
revealed strong significant positive correlations between the aforementioned cell subsets 
(transitional B vs. TFH-like cells: R=0.5964, respectively, p=0.0189 and transitional B 
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vs. IL-21+ TFH-like cells R=0.5857, respectively, p=0.0218) (Fig. 5a and 5b). Similar 
observations were found between the ratios of CD19+CD38+CD24+ mature-naive B and 
CD4+CXCR5+PD-1+IL-21+ TFH cells in pSS. A significant positive correlation was 
found in the whole pSS group (R=0.5058, respectively, p=0.0095; data not shown) and 
in patients with EGMs as well, nevertheless the association was more powerful in the 
latter case  (R=0.5536, respectively, p=0.0323) (Fig. 5c). 
 
Correlation analysis between peripheral TFH-like cells and certain B cell subsets in SLE 
We measured the association between CD4+CXCR5+ICOS+PD-1+ TFH-like cells and 
both CD19+IgD-CD27- DN B cells and CD19+CD38-CD24hiCD27+ primarily memory B 
cells in SLE. A significant negative correlation was observed between the percentages 
of DN B cells and TFH-like cells in SLE patients with SLEDAI<6 (R=-0.5758, 
respectively, p=0.0156) (Fig. 5d). Furthermore, a significant negative correlation was 
found between the ratios of primarily memory B cells and TFH-like cells also in the 
same subgroup (R=-0.6317, respectively, p=0.0065) (Fig. 5e). Of note, these differences 
were tendentiously observed in the whole SLE group as well, however the correlations 
were not significant (data not shown). On the other hand, a significant positive 
correlation revealed between the proportions of CD4+CXC5+IL-21+ T cells and 
CD19+CD38hiCD27hi plasmablasts in the whole SLE patient group (R=0.4110, 
respectively, p=0.0412) (Fig. 5f). 
 
Association of  peripheral TFH-like cells, B cell subsets with serological parameters 
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We examined the possible relationship between circulating TFH-like cells or IL-21 
producing TFH-like cells and serological markers (Table 1), moreover between certain B 
cell subsets and serological markers as well (Table 2).  
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Discussion 
 
Patients with pSS and SLE are characterised by fundamental disturbances in the 
proportion of different B cell subpopulations, both in the peripheral blood and the site of 
inflammation. In our study, we found a significant enrichment of CD19+IgD+CD27- 
naive B cells in the peripheral blood of both pSS and SLE patients compared to healthy 
individuals. This observation is consistent with previous reports 12-14 and indicate that 
early B cell tolerance checkpoints are significantly impaired in these autoimmune 
diseases; moreover the break of tolerogenic mechanism of this stage probably 
accelerates the mobilization of autoreactive naive B cells from the bone marrow to the 
periphery 15, 16.  
There is another major tolerance checkpoint during the maturation stage of immature B 
cells when transitional B cells overcome a negative selection. In healthy adults, only a 
little portion of peripheral B cells are CD19+CD38hiCD24hiCD27- transitional B cells 
and most of them belong to the mature-naive and memory B cell pool.  The pathologic 
accumulation of these cells may occur due to their increased exiting from the bone 
marrow or disturbed entrance into secondary lymphoid organs 17. In accordance with 
previous findings 17-19, we observed significant elevation in the percentages of 
transitional B cells in SLE patients, additionally, this cell population showed association 
with the disease activity. In pSS, the frequency of transitional B cells did not correlated 
with the presence of EGMs. However, when we divided pSS patients into subgroups 
based on the presence of anti-SSA/Ro autoantibodies, we observed significantly higher 
transitional B cell proportions in pSS patients with autoantibody positivity, and found a 
positive association between elevated cell ratios and serum IgG levels.  
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When the transitional B cells undergo maturation processes, mature-naive B cells are 
generated which circulate into B cell follicles in secondary lymphoid organs 20. Of note, 
the defect in early self-tolerance may also cause the expansion of circulating self-
reactive and polyreactive type of mature-naive B cell subset. In our study, we measured 
significantly higher percentages of CD19+CD38+CD24+ mature-naive B cells in SLE. 
Importantly, large numbers of autoreactive B cells occur among the mature-naive B cell 
compartment in SLE 21.  
We also confirmed that peripheral CD19+IgD+CD27+ non-switched memory B cells and 
CD19+IgD-CD27+ switched memory B cells are strongly diminished in both pSS and 
SLE 17, 22-24. Additionally, we revealed significant differences between the distributions 
of the two memory B cell compartments in the investigated diseases. In pSS patients, 
the proportion of switched memory B cells decreased significantly; while in SLE 
patients, the non-switched memory B cells reduced significantly. Furthermore, within 
pSS and SLE patient groups, a more pronounced reduction was observed in patients 
with EGMs or higher SLEDAI values. In addition, among SLE patients, individuals 
with active disease status exhibited a significant decrease in switched memory B cell 
subset, which underlines the importance of the changing distribution of B cell subsets 
during the disease course. The lower ratio of circulating memory B cells may be 
explained by their overexpression of chemokine molecules CXCR3 and CXCR4 which 
guide them into the inflamed tissues 12, 13, 25. Recent findings indicate that 
CD19+IgD+CD27+ non-switched memory B cells from SLE patients are in an activated 
state and exhibit elevated level of activation induced cytidine deaminase (AID), which 
promotes their differentiation into IgG-secreting plasma cells 12. The lower ratio of 
CD19+IgD-CD27+ switched memory B cells in pSS can be also explained by the 
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pronounced differentiation toward plasma cells or by the shed off CD27 from the 
surface of memory B cells 26. We also identified CD19+CD38-CD24hiCD27+ primarily 
memory B cells which similar to non-switched memory B cells showed a significant 
elevation in SLE patients with active disease status.  
We detected significantly increased CD19+IgD-CD27- DN B cells in SLE patients, while 
the ratio of DN B cells was significantly decreased in pSS patients. However, regarding 
the clinical features, these differences were found only in patients with a more 
pronounced disease course, such as high SLEDAI or the presence of EGMs. A previous 
report proposed that the presence of these cells could be the result of an extrafollicular 
differentiation process in secondary lymphoid organs. The expression of CD95 indicates 
that they are in an activated state; however their activation does not require T cell 
interaction. Furthermore, due to the expression of CXCR3, after receiving activation 
signals, DN B cells could migrate to inflamed tissues 27, 28. The proportion of 
CD19+CD38hiCD27hi plasmablasts were significantly decreased in pSS patients with 
EGMs, while their ratio was significantly elevated in SLE patients with SLEDAI>6.. 
This discrepancy may arise from the heightened expression of CXCR3 and CXCR4 on 
plasma cells and plasmablast of patients with pSS, which leads to their migration 
toward the site of inflammation or even the bone marrow 29-31. Moreover, in SLE, the 
differentiation toward plasmablasts is more pronounced, compared to pSS, and could be 
originated from both T-dependent and T-independent responses. 
TFH cells are crucial immune regulators in secondary lymphoid follicles by controlling 
B cell proliferation and differentiation. Since the measurement of human GC TFH cell 
from lymphoid follicles could be hardly performed, the investigation of circulating TFH-
like cells are widely accepted. In the last few years, a number of observations indicated 
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that circulating TFH cells represent a partial differentiated state, however they express 
TFH-related markers at lower intensity and maintain functional characteristic to promote 
B cell differentiation 32, 33. At the periphery, TFH-like cells may represent a memory 
CD4+ T cell condition, and according to certain cell surface molecules, including ICOS, 
PD-1 and CCR7, they can be subdivided into distinct subsets 34. In the present study, we 
revealed a significant increase in the proportion of peripheral CD4+CXCR5+ICOS+PD-
1+ TFH-like cells in pSS patients with EGMs compared to control values, while values of 
pSS patients without EGMs were similar to healthy individuals. Moreover, we also 
observed a significant difference between patients with and without EGMs. With this 
independent set of pSS cases, we reinforced our previous findings 6. When we divided 
patients into subgroups based on the presence of anti-SSA/Ro, we found significantly 
higher TFH-like cell percentages in autoantibody positive group. The same changes were 
measured in SLE, and circulating TFH-like cell percentages were significantly elevated 
in patients positive for anti-dsDNA, however there was no significant difference 
between the inactive and active status of the disease.  
As next step, we evaluated the proportion of IL-21 producing CD4+CXCR5+PD-1+ TFH-
like
 
cells and found a significant elevation in pSS patients with EGMs and/or anti-
SSA/Ro positivity. Similarly, a marked expansion was observed in SLE patients, which 
was independent from the disease status, however the tendency was more pronounced in 
patients with anti-dsDNA autoantibody. Previous investigations on TFH-like cells led to 
similar results 35-41, however the identification of these cell types are not fully 
characterized yet. For that reason, some differences could arise with regard to the 
number of cell surface markers or the exact percentages of TFH-like cells; nevertheless 
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there is broad agreement in that the expansion of TFH-like cells in peripheral blood 
could reflect the severity of autoimmune disorders. 
To get a better view on the significance of TFH-like cell expansion in pSS and SLE, we 
analysed the association between the proportion of TFH-like cells and other parameters. 
Our results revealed a positive correlation between circulating TFH-like cells and serum 
levels of IgG and RF. Additionally, IL-21 producing TFH-like cells showed a positive 
association with serum levels of circulating immune complexes in both pSS and SLE 
patients. These parameters are strongly related to the regulation of plasma cell 
generation which underlines the role of TFH cells in autoimmune diseases. Regarding B 
cell subsets, the frequency of transitional B cells correlated with the increased TFH-like 
cell and IL-21+ TFH-like cell percentages in pSS; furthermore, the level of mature-naive 
B cells also correlated with the increased ratio of TFH-like cells. These observations 
suggest that disturbances in early B cell tolerance mechanisms may lead to the 
peripheral expansion and further accumulation of these B cell subsets. The mutual 
cooperation between B cells and TFH cells potentially contributes to the development of 
characteristic pSS features. On the other hand, the expansion of circulating TFH-like 
cells negatively correlated with both primarily memory B cells and DN B cells in SLE 
patients, which indicates the role of TFH cells in B cell differentiation skewing toward 
plasma cell direction. By demonstrating a positive association between IL-21 producing 
CD4+CXCR5+ T cells and plasmablast, we underlined the importance of IL-21 in the 
pathogenesis of SLE.  
In the present study, we analysed the whole population of IL-10 producing B cells . The 
decreased IL-10 producing Breg cell percentages in pSS may elucidate our previous 
observations that despite of the increased peripheral IL-10 producing regulatory T (Tr1) 
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cell proportions, a significant decrease in soluble IL-10 level can be detected in the 
disease. We assume that along with the decrease IL-10 production of Breg cells, the 
intensification of a counterbalance-mechanism appears; thus, levels of IL-10 producing 
Tr1 cells increase as a feedback process attempting to compensate the progression of 
disproportional immune responses 42.  
In conclusion, our observations underline the essential role of the profound expansion of 
circulating TFH-like cells and their IL-21 production in combination with the 
characteristic abnormal distribution of peripheral B cell subsets disturbances in the 
pathogenesis of both pSS and SLE (Figure 5). We believe that these extensive 
experiments revealed the importance of TFH cells in these autoimmune diseases and 
provide valuable insight to invent novel therapeutic strategies targeting certain B cell 
subsets and suppressing TFH mediated responses. 
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Figure legends 
 
Figure 1. Comparative analysis of peripheral B cell subsets from pSS patients, SLE 
patients and healthy individuals. PBMCs were isolated from 25 pSS patients, 25 SLE 
patients and 21 healthy controls then were stained with labelled antibodies as described 
previously. Peripheral blood B cell subsets were quantified as their percentage in CD19+ 
lymphocyte population. Representative IgD-CD27 and CD38-CD24 dot plots indicating 
the distribution and percentages of different B cell subsets. (a) Percentages of 
CD19+IgD-CD27+ switched memory B cells in the overall pSS patient population 
(n=25), pSS with only glandular symptoms (n=10), pSS with EGMs (n=15), total SLE 
patient group (n=25), SLE with SLEDAI<6 (n=17), SLE with SLEDAI>6 (n=8) and 
control subjects (n=21). (b) Frequency of CD19+IgD+CD27+ non-switched memory B 
cells. (c) Proportions of CD19+IgD-CD27- DN B cells. (d) Ratio of CD19+IgD+CD27- 
naive B cells. (e) Distribution of CD19+CD38-CD24hiCD27+ primarily memory B cells. 
(f) Percentages of CD19+CD38hiCD24hiCD27- transitional B cells. (g) Proportion of 
CD19+CD38+CD24+ mature-naive B cells. (h) Frequency of CD19+CD38hiCD27hi 
plasmablasts. Each data point represents an individual subject, horizontal lines show the 
mean values with SD. Statistically significant differences are indicated by *, p < 0.05; 
**, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
 
Figure 2. Enumeration of circulating TFH-like cells in pSS patients, SLE patients and 
healthy subjects. PBMCs were isolated from 25 pSS patients, 25 SLE patients and 21 
healthy controls then were stained with labelled antibodies as described previously. 
Circulating TFH-like cells were assessed as their percentage in CD4+ lymphocyte 
population. Representative dot plots are shown the frequency of ICOS+PD-1+ and PD-
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1+IL-21+ cells within the CD4+CXCR5+ cell population. (a) Percentages of 
CD4+CXCR5+ICOS+PD-1+ TFH-like cells in the overall pSS patient population (n=25), 
pSS with only glandular symptoms (n=10), pSS with EGMs (n=15), total SLE patient 
group (n=25), SLE with SLEDAI<6 (n=17), SLE with SLEDAI>6 (n=8) and control 
subjects (n=21). (b) Ratio of CD4+CXCR5+ICOS+PD-1+ TFH-like cells according to the 
presence of autoantibodies; in anti-Ro/SSA antibody-negative group (n=16), anti-
Ro/SSA antibody-positive group (n=9), anti-dsDNA negative group (n=10), anti-
dsDNA positive group (n=15) and control subjects (n=21). (c) Distribution of IL-21 
producing CD4+CXCR5+ PD-1+ TFH-like cells. (d) Percentages of IL-21 producing 
CD4+CXCR5+ PD-1+ TFH-like cells according to the presence of autoantibodies in 
patients group. Each data point represents an individual subject, horizontal lines show 
the mean values with SD. Statistically significant differences are indicated by *, p < 
0.05; **, p < 0.01; ***, p < 0.001. 
 
Figure 3. Circulating TFH-like cells are associated with the expansion of IL-21 
producing TFH-like cells. Correlation between the percentages of 
CD4+CXCR5+ICOS+PD-1+ TFH-like cells and CD4+CXCR5+PD-1+IL-21+ TFH-like cells 
in patients with pSS (black dots with solid line) and SLE (clear dots with dashed line). 
 
Figure 4. Quantification of peripheral IL-10 producing B10 and B10PRO cells in pSS 
patients, SLE patients and healthy controls. PBMCs were isolated from 25 pSS patients, 
25 SLE patients and 21 healthy controls, then to gain B10 cell frequencies, cells were 
incubated with CpG+PIB for 5 h. B10+B10PRO cell maturation was induced with CpG 
stimulation for 48 h with PIB added during the last 5 h. Regarding the exact assessment 
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of IL-10 production, we used BFA and PIB alone controls during the procedure. 
Representative dot plots show IL-10 producing B cells in response to different 
conditions. (a) Percentages of IL-10+CD19+ B10 cells. (b) Percentages of IL-10+CD19+ 
B10 and B10PRO cells in pSS patients group (n=25), SLE patient group (n=25) and 
control group (n=21) in response to BFA, PIB or CpG+PIB. Results are presented as 
box and whiskers plot, horizontal lines show the mean values. Statistically significant 
differences are indicated by *, p < 0.05; **, p < 0.01; ns, no significant differences 
between patient and control groups within an experiment. Statistically significant 
differences are indicated by #, p<0.0001 between PIB alone and PIB+CpG stimulation 
within the groups. PIB: Phorbol 12-myristate 13-acetate [PMA] + Ionomycin + 
Brefeldin A 
 
Figure 5. Correlation analysis between peripheral TFH-like cells and transitional B cell 
subpopulations. (a) Correlation between the percentages of TFH-like cells and 
CD19+CD38hiCD24hiCD27- transitional B cells in pSS patients with EGMs. (b) 
Correlation between the percentages of IL-21 producing TFH-like cells and transitional B 
cells in pSS patients with EGMs. (c) Correlation between the proportions of IL-21 
producing TFH-like cells and CD19+CD38+CD24+ mature-naive B cells in pSS patients 
with EGMs. (d) Correlation between the ratios of TFH-like cells and CD19+IgD-CD27- 
DN B cells in SLE patients with SLEDAI<6. (e) Correlation between the frequencies of 
TFH-like cells and CD19+CD38-CD24hiCD27+ primarily memory B cells in SLE patients 
with SLEDAI<6. (f) Correlation between the percentages of IL-21 producing 
CD4+CXCR5+ T cells and CD19+CD38hiCD27hi plasmablasts in the whole SLE patients 
group. Each data point represents an individual subject. 
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Figure 6. Summarized model showing the outcome of disturbed tolerance during B cell 
development in pSS and SLE. In physiological circumstances, to avoid autoreactivity, 
during B cell development multiple tolerance checkpoints are applied for the selection 
of autoreactive B cells 43. Abnormalities in checkpoint regulation, along with 
hyperactivation of TFH cells and self-reactive B cells contribute to the development of 
autoimmunity in susceptible individuals. Breaking of early B-cell tolerance leads to 
consequential accumulation of transitional and naive B cells in the periphery. 
Perturbation of late peripheral tolerance in secondary lymphoid organs allows 
autoreactive mature B cells to undergo extrafollicular or germinal centre responses, 
which are supported by TFH cells, and differentiate into memory B cells or plasmablasts 
15, 44, 45
. Derailed B cell homeostasis and increased TFH cells responses manifest in 
characteristic changes in B cell distribution and accumulation of circulating TFH-like 
cell is pSS and SLE. 
 
Figure S1. Viability of the CpG exposed cells were determined by 7-
aminoactinomycin-D (7-AAD) staining using flow cytometric analysis. (a) 
Representative dot plots show the 7-AAD+ dead cells and 7-AAD- viable cells in the 
PBMC. Underneath, smaller dot plots indicate the differences in the presence of B cells 
among the viable or dead cell populations. (b) Representative dot plots show the 
frequency of CD19+7-AAD+ cells within the lymphocytes. (c) Percentages of 7-AAD+ 
(left) and CD19+7-AAD+ cells (right) in pSS patients group (n=5), SLE patient group 
(n=7) and control group (n=4) in response to BFA, PIB or CpG+PIB.  
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Figure S2. Evaluation of TFH markers on naive CD45RA+ T cells and active or memory 
CD45RA- T cells in pSS patients, SLE patients and healthy subjects. PBMCs were 
isolated from 9 pSS patients, 8 SLE patients and 6 healthy controls then were stained as 
described previously. Representative dot plots show the gating strategy for the 
determination of CD4+CD45RA- and CD4+CD45RA+ subsets. (a) Percentages of 
CXCR5+ICOS+ in the CD4+CD45RA- (left) and in the CD4+CD45RA+ (right) subsets. 
(b) Percentages of CXCR5+PD-1+ in the CD4+CD45RA- (left) and in the 
CD4+CD45RA+ (right) subsets. (c) Association between the ratio of CXCR5+ICOS+ 
cells and CXCR5+PD-1+ cells in the CD4+CD45RA- subset. Each data point represents 
an individual subject, horizontal lines show the mean values with SD.  
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Tables 
Table 1. Association of certain TFH-like cell proportions with serological parameters 
Association Disease Variable Correlation 
coefficient p-value 
Positive 
pSS 
CD4+CXCR5+ICOS+PD-1+ TFH-like cells  
vs. levels of serum IgG antibody 
Spearman 
R=0.6143 0.0018 ** 
CD4+CXCR5+ICOS+PD-1+ TFH-like cells  
vs. levels of serum RF 
Spearman 
R=0.6219 0.0101 * 
CD4+CXCR5+PD-1+IL-21+ TFH cells  
vs. levels of serum IC 
Pearson 
R=0.5734 0.0128 * 
SLE CD4
+CXCR5+IL-21+ TFH cells  
vs. levels of serum IC 
Spearman 
R=0.4723 0.0478 * 
 
 
Table 2. Association of certain B cell proportions with laboratory parameters 
Association Disease Variable Correlation 
coefficient p-value 
Positive 
pSS 
CD19+CD38hiCD24hiCD27- transitional B cells  
vs. levels of serum IgG 
Spearman 
R=0.4884 0.0181 * 
CD19+CD38hiCD27hi plasmablasts  
vs. levels of serum IC 
Spearman 
R=0.4907 0.0387 * 
SLE CD19
+CD38hiCD27hi plasmablasts  
vs. levels of serum anti-dsDNA 
Spearman 
R=0.5320 0.0090 ** 
Negative SLE CD19
+CD38hiCD24hiCD27- transitional B cells  
vs. levels of serum C3 
Pearson 
R=-0.4914 0.0172 * 
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